Day One Biopharmaceuticals full-year 2025 OJEMDA revenue rises

Day One Biopharmaceuticals

24/02/2026 21:13

Overview

Biopharmaceutical firm's full-year 2025 OJEMDA full-year 2025 net product revenue grew 172% yr/yr

Outlook

Company reaffirms 2026 U.S. net product revenue guidance at $225 mln to $250 mln

Day One expects mid-2026 Phase 1 data on Emi-Le for adenoid cystic carcinoma

Result Drivers

OJEMDA GROWTH - Fourth quarter prescription volumes increased to 1,394, with total 2025 prescriptions showing 181% growth versus 2024, indicating strong patient demand and prescriber adoption

PIPELINE EXPANSION - Acquisition of Mersana Therapeutics added Emi-Le to pipeline, currently in Phase 1 trial for adenoid cystic carcinoma

Company press release: ID:nGNX8zhVcm

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY EPS
-$1.04
FY Net Income
-$107.32 mln
FY Cash & Investments
$441.1 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Day One Biopharmaceuticals Inc is $24.50, about 109.4% above its February 23 closing price of $11.70

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)